Expertise in
9
conditions

Jong Y. Choi

Seoul St. Mary's Hospital, 
Seoul, KR 
Expertise in
9
conditions
Seoul St. Mary's Hospital, 
Seoul, KR 
OverviewLocationsClinical Research

Overview

Jong Choi practices in Seoul, Republic of Korea. Mr. Choi is highly rated in 9 conditions, according to our data. His top areas of expertise are Liver Cancer, Hepatitis B, Hepatitis, Liver Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 202 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Seoul St. Mary's Hospital, Seoul, Republic of Korea
Other Locations
Republic of Korea
Incheon St. Mary's Hospital, Incheon, Republic of Korea
Uijeongbu St. Mary's Hospital, Uijeongbu, Gyeonggi-do, Republic of Korea
Uijeongbu St. Mary's Hospital, Uijeongbu-si, Republic of Korea
Seoul St Mary's Hospital, 222, Banpo Daero, 06591, Seocho, Republic of Korea
Uijeongbu St. Mary's Hospital, Puch'on, Republic of Korea
Gangneung, Republic of Korea
Chuncheon, 200704, Republic of Korea
Yuseong, 305701, Republic of Korea
Daejeon, 305701, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm
A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Drug
Study Phase: Phase 3

202 Total Publications

Peripheral blood inflammatory score using a cytokine multiplex assay predicts clinical outcomes in patients treated with atezolizumab-bevacizumab for unresectable HCC.
Peripheral blood inflammatory score using a cytokine multiplex assay predicts clinical outcomes in patients treated with atezolizumab-bevacizumab for unresectable HCC.
Journal: Frontiers in immunology
Published: February 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Choi's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile